

Supplementary Material

Tables

Table S1 Studies that evaluated DDIs in lung cancer patients.

Study	Treatment	Total patients	Lung cancer patients	Kind of study
Riechelmann RP et Al. ⁸	iv CHT; mABs; OT	405	19 (5,0%)	retrospective
Van Leeuwen et Al ⁶	iv CHT; mABs; OT	278	23 (8,3%)	retrospective
Van Leeuwen et Al ⁵	os CHT; TKIs; OT	898	28 (3,1%)	retrospective
Van Leeuwen et Al ⁹	CHT; mABs; TKIs; OT	121	25 (8,3%) *	prospective
Lopez-Martin C et Al ¹³	CHT	75	17 (23%)	prospective
Rompelman FMV et Al ¹⁴	CHT	298	260 (86%)	prospective

Abbreviations: iv, intravenous; os, oral; CHT, chemotherapy; mABs, monoclonal antibodies; OT, hormone therapy; TKIs, tyrosine kinase inhibitors. * Lung cancer patients considered in the group "others".

Table S2 Identified DDIs involving EGFR tyrosine kinase inhibitors.


DDI total number	342
DDI requiring medical intervention	20
DDI involving EGFR TKIs requiring medical intervention	14
DDI requiring medical intervention	
Yes	14
No	78
Major DDI involving the main oncological treatment	Osimertinib + Escitalopram/Citalopram/Quetiapine/ Carbamazepine/Ivabradine/Fluoxetine Gefitinib + Ranitidine

Supplementary Material

Figures

Figure S1

a Kaplan-Meier describing PFS curve in all population.



b Kaplan-Meier describing OS curve in all population.

